We have located links that may give you full text access.
CASE REPORTS
JOURNAL ARTICLE
Photodynamic therapy for conjunctival ocular surface squamous neoplasia.
PURPOSE: To report the case about a patient with conjunctival ocular surface squamous neoplasia who responded well to ocular photodynamic therapy (PDT).
CASE: A 75-year-old man underwent PDT for his biopsy-proven conjunctival squamous cell dysplasia that was extending onto the cornea. Patient received 2 treatments of PDT with verteporfin (6 mg/m(2) body surface area, intravenously) with 2 months apart. The light dose was calculated as 50 J/cm(2). Whole lesion was irradiated 1 min after injection.
RESULTS: Half of the mass regressed after first PDT. Second PDT resulted in near-complete cure of remaining lesion within 2 weeks. The patient remained stable for the 13 months.
CONCLUSION: PDT may be useful in some cases of extensive ocular surface squamous neoplasia that is less than invasive.
CASE: A 75-year-old man underwent PDT for his biopsy-proven conjunctival squamous cell dysplasia that was extending onto the cornea. Patient received 2 treatments of PDT with verteporfin (6 mg/m(2) body surface area, intravenously) with 2 months apart. The light dose was calculated as 50 J/cm(2). Whole lesion was irradiated 1 min after injection.
RESULTS: Half of the mass regressed after first PDT. Second PDT resulted in near-complete cure of remaining lesion within 2 weeks. The patient remained stable for the 13 months.
CONCLUSION: PDT may be useful in some cases of extensive ocular surface squamous neoplasia that is less than invasive.
Full text links
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app